Inhibikase Therapeutics (IKT) Competitors

Inhibikase Therapeutics logo
$1.34 +0.05 (+3.46%)
As of 10:21 AM Eastern
This is a fair market value price provided by Massive. Learn more.

IKT vs. ARDX, COLL, ACHV, HELP, and ZVRA

Should you buy Inhibikase Therapeutics stock or one of its competitors? Inhibikase Therapeutics's main competitors and comparable companies include Ardelyx (ARDX), Collegium Pharmaceutical (COLL), Achieve Life Sciences (ACHV), Cybin (HELP), and Zevra Therapeutics (ZVRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Inhibikase Therapeutics compare to Ardelyx?

Inhibikase Therapeutics (NASDAQ:IKT) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

In the previous week, Inhibikase Therapeutics had 5 more articles in the media than Ardelyx. MarketBeat recorded 11 mentions for Inhibikase Therapeutics and 6 mentions for Ardelyx. Inhibikase Therapeutics' average media sentiment score of 0.53 beat Ardelyx's score of 0.05 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inhibikase Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ardelyx
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Inhibikase Therapeutics currently has a consensus price target of $4.75, suggesting a potential upside of 267.08%. Ardelyx has a consensus price target of $13.60, suggesting a potential upside of 348.84%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Inhibikase Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibikase Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
2.90
Ardelyx
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92

Inhibikase Therapeutics has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibikase Therapeutics$260K698.11-$48.26M-$0.40N/A
Ardelyx$468.22M1.63-$61.60M-$0.22N/A

Inhibikase Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -11.85%. Ardelyx's return on equity of -35.30% beat Inhibikase Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Inhibikase TherapeuticsN/A -40.53% -38.44%
Ardelyx -11.85%-35.30%-10.23%

Inhibikase Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Inhibikase Therapeutics beats Ardelyx on 9 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, Inhibikase Therapeutics had 4 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 11 mentions for Inhibikase Therapeutics and 7 mentions for Collegium Pharmaceutical. Inhibikase Therapeutics' average media sentiment score of 0.53 beat Collegium Pharmaceutical's score of -0.24 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Collegium Pharmaceutical
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inhibikase Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Collegium Pharmaceutical currently has a consensus price target of $44.00, indicating a potential upside of 75.85%. Inhibikase Therapeutics has a consensus price target of $4.75, indicating a potential upside of 267.08%. Given Inhibikase Therapeutics' higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Collegium Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
Inhibikase Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
2.90

Collegium Pharmaceutical has a net margin of 4.68% compared to Inhibikase Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 85.14% beat Inhibikase Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical4.68% 85.14% 13.80%
Inhibikase Therapeutics N/A -40.53%-38.44%

Collegium Pharmaceutical has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$780.57M1.00$62.87M$1.0025.02
Inhibikase Therapeutics$260K698.11-$48.26M-$0.40N/A

Summary

Collegium Pharmaceutical and Inhibikase Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Achieve Life Sciences?

Inhibikase Therapeutics (NASDAQ:IKT) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Inhibikase Therapeutics had 11 more articles in the media than Achieve Life Sciences. MarketBeat recorded 11 mentions for Inhibikase Therapeutics and 0 mentions for Achieve Life Sciences. Inhibikase Therapeutics' average media sentiment score of 0.53 beat Achieve Life Sciences' score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Inhibikase Therapeutics Positive
Achieve Life Sciences Neutral

Inhibikase Therapeutics has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibikase Therapeutics$260K698.11-$48.26M-$0.40N/A
Achieve Life SciencesN/AN/A-$54.65M-$1.55N/A

Inhibikase Therapeutics presently has a consensus price target of $4.75, suggesting a potential upside of 267.08%. Achieve Life Sciences has a consensus price target of $15.50, suggesting a potential upside of 131.17%. Given Inhibikase Therapeutics' higher possible upside, equities research analysts clearly believe Inhibikase Therapeutics is more favorable than Achieve Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibikase Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
2.90
Achieve Life Sciences
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

Inhibikase Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market.

Inhibikase Therapeutics' return on equity of -40.53% beat Achieve Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Inhibikase TherapeuticsN/A -40.53% -38.44%
Achieve Life Sciences N/A -511.12%-82.35%

Summary

Inhibikase Therapeutics beats Achieve Life Sciences on 11 of the 15 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Cybin?

Cybin (NASDAQ:HELP) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Inhibikase Therapeutics' return on equity of -40.53% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
CybinN/A -92.12% -85.90%
Inhibikase Therapeutics N/A -40.53%-38.44%

Inhibikase Therapeutics has higher revenue and earnings than Cybin. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CybinN/AN/A-$148M-$3.04N/A
Inhibikase Therapeutics$260K698.11-$48.26M-$0.40N/A

Cybin has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Cybin presently has a consensus target price of $47.33, indicating a potential upside of 621.11%. Inhibikase Therapeutics has a consensus target price of $4.75, indicating a potential upside of 267.08%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Inhibikase Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cybin
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Inhibikase Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
2.90

17.9% of Cybin shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cybin and Cybin both had 11 articles in the media. Inhibikase Therapeutics' average media sentiment score of 0.53 beat Cybin's score of -0.05 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cybin
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inhibikase Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Inhibikase Therapeutics beats Cybin on 8 of the 14 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Zevra Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 3.7% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Inhibikase Therapeutics presently has a consensus target price of $4.75, indicating a potential upside of 267.08%. Zevra Therapeutics has a consensus target price of $23.86, indicating a potential upside of 163.47%. Given Inhibikase Therapeutics' higher possible upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than Zevra Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibikase Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
2.90
Zevra Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Zevra Therapeutics had 7 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 18 mentions for Zevra Therapeutics and 11 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.53 beat Zevra Therapeutics' score of -0.03 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inhibikase Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zevra Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral

Inhibikase Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Zevra Therapeutics has a net margin of 52.80% compared to Inhibikase Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.64% beat Inhibikase Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Inhibikase TherapeuticsN/A -40.53% -38.44%
Zevra Therapeutics 52.80%54.64%37.84%

Zevra Therapeutics has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibikase Therapeutics$260K698.11-$48.26M-$0.40N/A
Zevra Therapeutics$106.47M5.06$83.23M$1.197.61

Summary

Zevra Therapeutics beats Inhibikase Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IKT vs. The Competition

MetricInhibikase TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$171.13M$13.27B$7.57B$11.65B
Dividend YieldN/A2.60%2.48%4.74%
P/E Ratio-3.0527.1633.0728.17
Price / Sales698.116.838.295.46
Price / CashN/A15.5320.7221.66
Price / Book0.965.294.423.65
Net Income-$48.26M$2.87B$3.51B$394.00M
7 Day Performance-14.87%-5.18%-5.54%-5.64%
1 Month Performance-24.33%-7.80%-8.71%-9.48%
1 Year Performance-15.42%-6.75%-1.46%-6.81%

Inhibikase Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IKT
Inhibikase Therapeutics
2.5234 of 5 stars
$1.35
+3.5%
$4.75
+253.2%
-16.7%$188.66M$260KN/A35
ARDX
Ardelyx
3.2953 of 5 stars
$2.93
+1.7%
$13.90
+374.4%
-45.1%$827.02M$407.32MN/A489
COLL
Collegium Pharmaceutical
3.4957 of 5 stars
$24.71
+2.1%
$44.88
+81.6%
-43.3%$770.59M$780.57M3.39423
ACHV
Achieve Life Sciences
1.4021 of 5 stars
$6.78
+0.9%
$15.50
+128.6%
+55.2%$718.26MN/AN/A28
HELP
Cybin
3.9902 of 5 stars
$9.37
+4.6%
$47.33
+405.2%
N/A$692.73MN/AN/A100

Related Companies and Tools


This page (NASDAQ:IKT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners